GENEVA, Switzerland and BOSTON, MA -- May 6, 2021 -- ObsEva SA (NASDAQ: 
OBSV) (SIX: OBSN), a biopharmaceutical company developing and 
commercializing novel therapies to improve women's reproductive health, 
today announced the appointment of Clive Bertram as Chief Commercial 
Officer and member of ObsEva's Executive Committee, effective May 10, 
2021. Wim Souverijns has served as Chief Commercial Officer of ObsEva 
since November 2018 and will leave the Company on June 30, 2021 to 
pursue a new opportunity. He will work to ensure a smooth transition 
with Clive Bertram. 
 
   "We are delighted to welcome Clive to the executive team, especially at 
such an exciting time for the Company," said Brian O'Callaghan, Chief 
Executive Officer of ObsEva. "Clive has a demonstrated track record of 
leadership and I am confident he will play a key role in further 
strengthening our relationships with investors and potential partners as 
we become a commercial company and prepare for the launch of Yselty in 
Europe, as well as the filing of a new drug application in the U.S. for 
the treatment of heavy menstrual bleeding and pain associated with 
uterine fibroids in pre-menopausal women. On behalf of the Board of 
Directors and Executive team, I would also like to thank Wim Souverijns 
for his leadership and contributions to the Company during his two plus 
year tenure at ObsEva." 
 
   Clive Bertram joins ObsEva with nearly 30 years of experience in 
commercialization, strategic, corporate and business development in the 
pharmaceutical industry. Most recently, he served as Chief Commercial 
Officer at Petra Pharma and Sangart. Clive also served as an independent 
consultant leading client thinking for strategic and marketing planning 
insight as well as launch excellence and implementation. Prior to his 
Chief Commercial Officer roles, Clive held senior management positions 
at Pharmion Limited, Chiron Biopharmaceuticals, Celltech and Eli Lilly. 
He holds a Bachelor of Science in Pharmacology & Chemistry from the 
University of Sheffield and will operate out of the UK. 
 
   "I am excited to be joining as Chief Commercial Officer at such an 
important time for the Company, as we prepare for the launch of its lead 
product, Yselty, for uterine fibroids, in Europe and subsequently the 
U.S., and plan for future commercialization. I look forward to working 
with the team on this exciting journey," said Clive Bertram. 
 
   About ObsEva 
 
   ObsEva is a biopharmaceutical company developing and commercializing 
novel therapies to improve women's reproductive health and pregnancy. 
Through strategic in-licensing and disciplined drug development, ObsEva 
has established a late-stage clinical pipeline with development programs 
focused on treating endometriosis, uterine fibroids and preterm labor. 
ObsEva is listed on the Nasdaq Global Select Market and is trading under 
the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is 
trading under the ticker symbol "OBSN". For more information, please 
visit www.ObsEva.com. 
 
   Cautionary Note Regarding Forward Looking Statements 
 
   Any statements contained in this press release that do not describe 
historical facts may constitute forward-looking statements as that term 
is defined in the Private Securities Litigation Reform Act of 1995. 
These statements may be identified by words such as "believe," "expect," 
"may," "plan," "potential," "will," and similar expressions, and are 
based on ObsEva's current beliefs and expectations. These 
forward-looking statements include expectations regarding the clinical 
development of and commercialization plans for ObsEva's product 
candidates, regulatory and development milestones, including the 
potential timing of regulatory submissions to the EMA and FDA, the 
timing of and ObsEva's ability to obtain and maintain regulatory 
approvals for its product candidates and the results of interactions 
with regulatory authorities. These statements involve risks and 
uncertainties that could cause actual results to differ materially from 
those reflected in such statements. Risks and uncertainties that may 
cause actual results to differ materially include uncertainties inherent 
in the conduct of clinical trials, clinical development and related 
interactions with regulators, ObsEva's reliance on third parties over 
which it may not always have full control, the impact of the novel 
coronavirus outbreak, and other risks and uncertainties that are 
described in the Risk Factors section of ObsEva's Annual Report on Form 
20-F for the year ended December 31, 2020 filed with the Securities and 
Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva 
makes with the SEC. These documents are available on the Investors page 
of ObsEva's website at www.ObsEva.com. Any forward-looking statements 
speak only as of the date of this press release and are based on 
information available to ObsEva as of the date of this release, and 
ObsEva assumes no obligation to, and does not intend to, update any 
forward-looking statements, whether as a result of new information, 
future events or otherwise. 
 
 
 
 
 
   For further information, please contact: 
 
   CEO Office contact 
 
   Shauna Dillon 
 
   Shauna.dillon@obseva.ch 
https://www.globenewswire.com/Tracker?data=lhhiCIR03nKBcekRm-a171qEbxUkKfu6mKZlyJApiCK2z5Jx0551gKNOOVfkqgouZ2qBXx8bSM1EqHcQvIbNT-4ybuM5TU5ZgaJnHxks1Sk= 
 
 
   +41 22 552 1550 
 
   Investor Contact: 
 
   Joyce Allaire 
 
   jallaire@lifesciadvisors.com 
https://www.globenewswire.com/Tracker?data=eNaA4GuHtIPHwAc1ygfI7Df1-PcHr2HlTlrXOReKKmwYNXoaTvrlY11FYUjG-PmeZBJyzhIWcOzEIbD-UIlOn3vDmA7l5KPC3SVa0mNouQByq0k1PBjOA5GVLxL4H2Om 
 
 
   +1 (617)-435-6602 
 
 
 
 
 
 
 
   Attachment 
 
 
   -- Press Release in Pdf 
      https://ml-eu.globenewswire.com/Resource/Download/95442a70-c2a0-4e6c-ba71-87d2b01f62dc

(END) Dow Jones Newswires

May 06, 2021 00:55 ET (04:55 GMT)